APA (7th ed.) Citation

J, G., AC, M., Z, W., HH, C., EP, M., JJ, W., . . . KT, F. (2024). Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2. JCO precision oncology, 8, e2300407. https://doi.org/10.1200/PO.23.00407

Chicago Style (17th ed.) Citation

J, Gong, et al. "Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2." JCO Precision Oncology 8 (2024): e2300407. https://doi.org/10.1200/PO.23.00407.

MLA (9th ed.) Citation

J, Gong, et al. "Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2." JCO Precision Oncology, vol. 8, 2024, p. e2300407, https://doi.org/10.1200/PO.23.00407.